Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
| Autor: | Dullaart RP; University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands. r.p.f.dullaart@int.umcg.nl, de Vries R, Voorbij HA, Sluiter WJ, van Tol A |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European journal of clinical investigation [Eur J Clin Invest] 2009 Mar; Vol. 39 (3), pp. 200-3. |
| DOI: | 10.1111/j.1365-2362.2009.02090.x |
| Abstrakt: | Background: The high-density lipoprotein (HDL)-associated anti-oxidative and anti-inflammatory enzyme, paraoxonase-I, has been found previously to be lower in type 2 diabetes mellitus. We studied whether statin and fibrate treatment, alone and in combination, affect serum paraoxonase-I activity in conjunction with changes in HDL cholesterol in diabetic patients. Subjects and Methods: A placebo-controlled crossover study was carried out in 14 type 2 diabetic patients to test the effect of 8 weeks of active treatment with simvastatin (40 mg daily), bezafibrate (400 mg daily), and their combination on serum paraoxonase-I activity, measured as its activity towards arylesterase and paraoxon. Serum paraoxonase-I activity was also compared between these diabetic patients and 49 non-diabetic control subjects. Results: Serum arylesterase activity was lower in type 2 diabetic patients compared to control subjects (P < 0.001), but the difference in paraoxonase activity was not significant (P = 0.22). Neither arylesterase (P = 0.24) nor paraoxonase activity (P = 0.37) was increased in response to treatment, despite higher HDL cholesterol and apolipoprotein A-I during combination therapy (P < 0.05 for both). Conclusion: Short-term administration of simvastatin and bezafibrate, even when combined, is ineffective in raising serum paraoxonase-I activity in type 2 diabetes. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|